Fundación Respirar ( Site 0302)

Buenos Aires, Buenos Aires F.D. C1426ABP

0 studies enrolling now · 1 studies all time

What they study most

Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma

Studies at this site

• A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) — Running, not enrolling